Client Alerts & Insights
FinCEN Confirms Nationwide Pause of Corporate Transparency Act and BOI Reporting Requirements
December 12, 2024
Entities should continue preparing to comply with BOI reporting requirements.
On December 10, 2024, the Financial Crimes Enforcement Network (FinCEN) alerted businesses that, for now, they do not need to report their beneficial ownership information (BOI). This alert followed the U.S. District Court for the Eastern District of Texas’s nationwide injunction blocking enforcement of the Corporate Transparency Act (CTA), which we detailed in a prior bulletin.
FinCEN maintains that the CTA is constitutional but confirmed that companies will not be subject to liability for failing to comply with BOI reporting requirements, so long as the Texas Top Cop Shop injunction remains in force. Texas Top Cop Shop v Garland et al., 4:24-cv-00478 (Dec. 3, 2024).
This injunction and explanatory alert from FinCEN both come only a few weeks before the January 1, 2025, deadline for businesses to file their BOI reports.
Texas Top Cop Shop is not the only case challenging the CTA currently working its way through the courts. Last spring, the Northern District of Alabama issued a narrow injunction blocking enforcement against the plaintiffs, which is currently on appeal in the Eleventh Circuit. The government is similarly expected to appeal the nationwide injunction.
Due to the uncertainty surrounding the CTA’s fate, companies should continue working with knowledgeable counsel to prepare for the potential reinstatement of the BOI reporting requirements. If you have questions regarding the CTA or the impact of the Texas Top Cop Shop decision, the White Collar and Corporate & Securities Practice Groups at Benesch are here to help.
Marisa T. Darden at mdarden@beneschlaw.com or 216.363.4440.
Robert J. Kolansky at rkolansky@beneschlaw.com or 216.363.4575.
Jennifer L. Stapleton at jstapleton@beneschlaw.com or 216.363.4428.
Connie A. Porter at cporter@beneschlaw.com or 216.363.4433.
Latest News
Medical First, Recreational Later? DOJ’s Cannabis Order and the Stakes Ahead
DOJ’s April 2026 order immediately moved FDA-approved and state-licensed medical cannabis to Schedule III, removing harsh tax penalties for medical operators, while leaving adult-use cannabis under stricter Schedule I controls pending further administrative review.
New Sentencing Guidelines for Economic Crimes Effective November 1, 2026
In March we reported on the U.S. Sentencing Commission’s proposed amendments to the Federal Sentencing Guidelines (the “Guidelines”). On April 16, 2026, the bipartisan United States Sentencing Commission (the “Commission”) voted unanimously to adopt that package of amendments, without modification.
Judicial Green Light: Court Upholds NLRB’s Cemex Decision
On April 21st, 2026, the U.S. Court of Appeals for the Ninth Circuit upheld the National Labor Relations Board’s (“NLRB”) decision in Cemex Construction Materials Pacific, LLC., reinforcing a significant shift in federal labor law governing union recognition and employer conduct during organizing campaigns.
The LEAD Model—Kidney Care’s Value-Based Care Journey LEADs Here
The new LEAD Model, launching in 2027, is CMS’s next-generation value-based care framework for kidney care, integrating CKD and ESRD patients into standard ACOs with a 10-year benchmark period, new payment options and greater flexibility for nephrology-led organizations.